Visual outcome, local tumour control, and eye preservation after 106Ru/Rh brachytherapy for choroidal melanoma

Acta Oncologica

Volumn 45, Issue 3, 2006, Pages 285-293

  Isager, Peter ^a   Ehlers, Niels ^a   Urbak, Steen F ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

RHODIUM; RUTHENIUM 106;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CHOROID MELANOMA; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CHOROID NEOPLASMS; EYE; EYE ENUCLEATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RHODIUM; RUTHENIUM; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33646417921     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500468950     Document Type: Article

References (54)

1. Isager P, Østerlind A, Engholm G, Heegaard S, Lindegaard J, Overgaard J, et al. Malignant melanoma in the ocular region in Denmark 1943-97. Incidence and validation study. Ophthal Epidemiol 2005;12:223-32.
2. The Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001;119:969-82.
3. Augsburger JJ, Schneider S, Freire J, Brady LW. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: Results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol 1999;237:558-67.
4. Courdi A, Caujolle JP, Grange JD, Diallo-Rosier L, Sahel J, Bacin F, et al. Results of proton therapy of uveal melanomas treated in Nice. Int J Radiat Oncol Biol Phys 1999;45:5-11.
5. Seddon JM, Gragoudas ES, Egan KM, Glynn RJ, Howard S, Fante RG, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology 1990;97:769-77.
6. Castro JR, Char DH, Petti PL, Daftari IK, Quivey JM, Singh RP, et al. 15 years experience with helium ion radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 1997;39:989-96.
7. Foulds WS, Damato BE, Burton RL. Local resection versus enucleation in the management of choroidal melanoma. Eye 1987;1(Pt 6):676-9.
8. Shields JA, Shields CL, Shah P, DePotter P. Current alternatives in the management of posterior uvea melanomas. Trans Pa Acad Ophthalmol Otolaryngol 1990;42:938-44.
9. Shields JA, Shields CL. Current management of posterior uveal melanoma. Mayo Clin Proc 1993;68:1196-200.
10. Damato BE. An approach to the management of patients with uveal melanoma. Eye 1993;7(Pt 3):388-97.
11. Union Internationale Contre le Cancer. TNM Classification of Malignant Tumours 5th edition. 1997.
12. The Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol 1998;125:745-66.
13. Seregard S, af Trampe E, Lax I, Kock E, Lundell G. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience. Acta Ophthalmol Scand 1997;75:11-6.
14. The Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology 2001;108:348-66.
15. Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S. Ruthenium brachytherapy for uveal melanoma, 1979-2003: Survival and functional outcomes in the Swedish population. Ophthalmology 2005;112:834-40.
16. Shields CL, Shields JA, Cater J, Gündüz K, Miyamoto C, Micaily B, et al. Plaque radiotherapy for uveal melanoma: Long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 2000;118:1219-28.
17. Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, et al. Plaque radiotherapy for large posterior uveal melanomas (>or = 8-mm thick) in 354 consecutive patients. Ophthalmology 2002;109:1838-49.
18. Lommatzsch PK, Werschnik C, Schuster E. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2000;238:129-37.
19. Bornfeld N, Chauvel P, Sauerwein W, Friedrichs W, Tiburtius T, Wessing A, et al. Metastatic disease, eye retention and visual function in conservative treatment of uveal melanoma. Front Radiat Ther Oncol 1997;30:97-110.
20. Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology 1999;106:1579-87.
21. Lommatzsch PK, Lommatzsch R. Treatment of juxtapapillary melanomas. Br J Ophthalmol 1991;75:715-7.
22. Damato BE, Paul J, Foulds WS. Predictive factors of visual outcome after local resection of choroidal melanoma. Br J Ophthalmol 1993;77:616-23.
23. Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol 1996;80:102-8.
24. Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999;117:609-14.
25. Fontanesi J, Meyer D, Xu S, Tai D. Treatment of choroidal melanoma with I-125 plaque. Int J Radiat Oncol Biol Phys 1993;26:619-23.
26. Lommatzsch PK. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years' experience. Br J Ophthalmol 1986;70:844-51.
27. Summanen P, Immonen I, Kivela T, Tommila P, Heikkonen J, Tarkkanen A. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol 1996;80:732-9.
28. Jones R, Gore E, Mieler W, Murray K, Gillin M, Albano K, et al. Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: Dose and dose rate effects. Int J Radiat Oncol Biol Phys 2002;52:989-95.
29. De Potter P, Shields CL, Shields JA, Cater JR, Brady LW Plaque radiotherapy for juxtapapillary choroidal melanoma. Visual acuity and survival outcome. Arch Ophthalmol 1996;114:1357-65.
30. Lommatzsch PK, Alberti W, Lommatzsch R, Rohrwacher F. Radiation effects on the optic nerve observed after brachytherapy of choroidal melanomas with 106Ru/106Rh plaques. Graefes Arch Clin Exp Ophthalmol 1994;232:482-7.
31. Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 1999;127:579-89.
32. Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 1999;106:1571-7.
33. Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol 1999;117:170-7.
34. Char DH, Kroll S, Quivey JM, Castro J. Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy. Br J Ophthalmol 1996;80:117-24.
35. Summanen P, Immonen I, Kivela T, Tommila P, Heikkonen J, Tarkkanen A. Visual outcome of eyes with malignant melanoma of the uvea after ruthenium plaque radiotherapy. Ophthalmic Surgery and Lasers 1995;26:449-60.
36. Summanen P, Immonen I, Heikkonen J, Tommila P, Laatikainen L, Tarkkanen A. Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy. Ophthalmic Surgery 1993;24:82-90.
37. Rouberol F, Roy P, Kodjikian L, Gerard JP, Jean-Louis B, Grange JD. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). Am J Ophthalmol 2004;137:893-900.
38. Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after (106)Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005.
39. The Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002;109:2197-206.
40. Kleineidam M, Guthoff R, Bentzen SM. Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques. Radiother Oncol 1993;28:148-56.
41. Muller RP, Busse H, Potter R, Kroll P, Haverkamp U. Results of high dose 106-ruthenium irradiation of choroidal melanomas. Int J Radiat Oncol Biol Phys 1986;12:1749-55.
42. Tjho-Heslinga RE, Davelaar J, Kemme HM, de Vroome H, Oosterhuis JA, Bleeker JC, et al. Results of ruthenium irradiation of uveal melanomas: The Dutch experience. Radiother Oncol 1999;53:133-7.
43. Quivey JM, Augsburger J, Snelling L, Brady LW. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Cancer 1996;77:2356-62.
44. Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993;100:1547-54.
45. Char DH, Kroll S, Phillips TL, Quivey JM. Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 2002;109:1850-4.
46. Munzenrider JE, Gragoudas ES, Seddon JM, Sisterson J, McNulty P, Birnbaum S, et al. Conservative treatment of uveal melanoma: Probability of eye retention after proton treatment. Int J Radiat Oncol Biol Phys 1988;15:553-8.
47. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002;120:1665-71.
48. Gragoudas ES, Egan KM, Walsh SM, Regan S, Munzenrider JE, Taratuta V. Lens changes after proton beam irradiation for uveal melanoma. Am J Ophthalmol 1995;119:157-64.
49. Shields CL, Shields JA, Perez N, Singh AD, Cater J. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: Outcomes and limitations. Ophthalmology 2002;109:225-34.
50. Seregard S, Landau I. Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy for choroidal melanoma. Acta Ophthalmol Scand 2001;79:19-22.
51. Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: Tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 2002;120:933-40.
52. Journee-de Korver JG, Keunen JE. Thermotherapy in the management of choroidal melanoma. Prog Retin Eye Res 2002;21:303-17.
53. Dieckmann K, Georg D, Zehetmayer M, Bogner J, Georgopoulos M, Potter R. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol 2003;67:199-206.
54. Shields CL, Shields JA, Karlsson U, Markoe AM, Brady LW. Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Clinical findings. Ophthalmology 1989;96:919-23.